Xtant Medical Q2 2025 revenue $35.4M (+18% YoY), net income $3.6M, raises FY guidance

Xtant Medical Holdings, Inc.

2025-Q2 EPS reported $0.02 vs consensus -$0.01 ▲ beat (+296.1%)

Revenue $35.4M up 18% YoY; gross margin improved to 68.6% from 62.1%.
Net income $3.6M ($0.02 diluted EPS) vs net loss $3.9M in Q2 2024.
Adjusted EBITDA $6.9M vs loss of $0.6M; operating cash flow $1.2M vs use of $5.1M.
FY2025 revenue guidance raised to $131-$135M (prior $127-$131M), growth 11%-15%.
Announced sale of non-core Coflex/CoFix/OUS assets to Companion Spine for ~$19.2M.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.